Superiority of tenofovir alafenamide fumarate over entecavir for serum HBsAg level reduction in patients with chronic HBV infection: A 144-week outcome study after switching of the nucleos(t)ide analog

BACKGROUND: To evaluate the long-term efficacy of switching of the nucleos(t)ide analog used for treatment from entecavir (ETV) to tenofovir alafenamide fumarate (TAF) in patients with chronic HBV infection. METHODS: A total of 103 patients with serum HBsAg levels of ≥100 IU/mL who had received ETV...

Descripción completa

Detalles Bibliográficos
Autores principales: Uchida, Yoshihito, Nakao, Masamitsu, Yamada, Shunsuke, Tsuji, Shohei, Uemura, Hayato, Kouyama, Jun-ichi, Naiki, Kayoko, Sugawara, Kayoko, Nakayama, Nobuaki, Imai, Yukinori, Tomiya, Tomoaki, Mochida, Satoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8856517/
https://www.ncbi.nlm.nih.gov/pubmed/35180213
http://dx.doi.org/10.1371/journal.pone.0262764

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8856517/
https://www.ncbi.nlm.nih.gov/pubmed/35180213
http://dx.doi.org/10.1371/journal.pone.0262764

Ejemplares similares